Artikel mit Open-Access-Mandaten - alessandra mangiaWeitere Informationen
Nicht verfügbar: 4
Phyto-liposomes as nanoshuttles for water-insoluble silybin–phospholipid complex
R Angelico, A Ceglie, P Sacco, G Colafemmina, M Ripoli, A Mangia
International journal of pharmaceutics 471 (1-2), 173-181, 2014
Mandate: Government of Italy
Gene expression profile of Huh‐7 cells expressing hepatitis C virus genotype 1b or 3a core proteins
V Pazienza, S Clément, P Pugnale, S Conzelmann, S Pascarella, ...
Liver International 29 (5), 661-669, 2009
Mandate: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Effect of hepatitis B virus on steatosis in hepatitis C virus co‐infected subjects: A multi‐centre study and systematic review
N Goossens, C de Vito, A Mangia, S Clément, G Cenderello, F Barrera, ...
Journal of viral hepatitis 25 (8), 920-929, 2018
Mandate: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens
N Bhardwaj, M Ragonnet‐Cronin, B Murrell, K Chodavarapu, R Martin, ...
Journal of viral hepatitis 25 (4), 344-353, 2018
Mandate: US National Institutes of Health, UK Biotechnology and Biological Sciences …
Verfügbar: 44
Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
JJ Feld, IM Jacobson, C Hézode, T Asselah, PJ Ruane, N Gruener, ...
New England Journal of Medicine 373 (27), 2599-2607, 2015
Mandate: National Institute for Health Research, UK
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ...
New England Journal of Medicine 373 (27), 2608-2617, 2015
Mandate: National Institute for Health Research, UK
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome
S Zeuzem, M Mizokami, S Pianko, A Mangia, KH Han, R Martin, ...
Journal of hepatology 66 (5), 910-918, 2017
Mandate: US National Institutes of Health
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts
P Duggal, CL Thio, GL Wojcik, JJ Goedert, A Mangia, R Latanich, AY Kim, ...
Annals of internal medicine 158 (4), 235-245, 2013
Mandate: US National Institutes of Health
SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C
G Sebastiani, P Halfon, L Castera, S Pol, DL Thomas, A Mangia, ...
Hepatology 49 (6), 1821-1827, 2009
Mandate: US National Institutes of Health
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ...
Nature communications 6 (1), 6422, 2015
Mandate: National Health and Medical Research Council, Australia
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes
E Terczyńska-Dyla, S Bibert, FHT Duong, I Krol, S Jørgensen, E Collinet, ...
Nature communications 5 (1), 5699, 2014
Mandate: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung …
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
K Thabet, A Asimakopoulos, M Shojaei, M Romero-Gomez, A Mangia, ...
Nature communications 7 (1), 12757, 2016
Mandate: National Health and Medical Research Council, Australia, Deutsche …
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes
M Eslam, A Mangia, T Berg, HLY Chan, WL Irving, GJ Dore, ML Abate, ...
Hepatology 64 (1), 34-46, 2016
Mandate: National Health and Medical Research Council, Australia, UK Medical Research …
Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 Astral trials
J Grebely, GJ Dore, S Zeuzem, RJ Aspinall, R Fox, L Han, J McNally, ...
Clinical Infectious Diseases 63 (11), 1479-1481, 2016
Mandate: US National Institutes of Health, National Health and Medical Research …
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
M Eslam, D McLeod, KS Kelaeng, A Mangia, T Berg, K Thabet, WL Irving, ...
Nature Genetics 49 (5), 795-800, 2017
Mandate: National Health and Medical Research Council, Australia, UK Medical Research …
Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies
VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ...
Liver international 37 (4), 514-528, 2017
Mandate: Government of Italy
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts
A Mangia, S Milligan, M Khalili, S Fagiuoli, SD Shafran, F Carrat, D Ouzan, ...
Liver International 40 (8), 1841-1852, 2020
Mandate: US National Institutes of Health, National Institute of Health and Medical …
FibroGENE: A gene-based model for staging liver fibrosis
M Eslam, AM Hashem, M Romero-Gomez, T Berg, GJ Dore, A Mangia, ...
Journal of hepatology 64 (2), 390-398, 2016
Mandate: National Health and Medical Research Council, Australia, UK Medical Research …
The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B
K Thabet, HLY Chan, S Petta, A Mangia, T Berg, A Boonstra, WP Brouwer, ...
Hepatology 65 (6), 1840-1850, 2017
Mandate: National Health and Medical Research Council, Australia
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection
M Ramos-Casals, AL Zignego, C Ferri, P Brito-Zerón, S Retamozo, ...
Journal of hepatology 66 (6), 1282-1299, 2017
Mandate: Government of Spain
Angaben zur Publikation und Finanzierung werden automatisch von einem Computerprogramm ermittelt